PTEN gene expression and mutations in the PIK3CA gene as predictors of clinical benefit to anti-epidermal growth factor receptor antibody therapy in patients with KRAS wild-type metastatic colorectal cancer.
about
Biomarkers predicting resistance to epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer with wild-type KRASColorectal cancer tumour markers and biomarkers: Recent therapeutic advancesPharmacologic resistance in colorectal cancer: a reviewPrecision medicine in colorectal cancer: the molecular profile alters treatment strategiesPIK3CA mutation is associated with poor survival among patients with metastatic colorectal cancer following anti-EGFR monoclonal antibody therapy: a meta-analysis.The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis.The biological complexity of colorectal cancer: insights into biomarkers for early detection and personalized careOncogenic fingerprint of epidermal growth factor receptor pathway and emerging epidermal growth factor receptor blockade resistance in colorectal cancerPanitumumab in Metastatic Colorectal Cancer: The Importance of Tumour RAS StatusPCR-based assays versus direct sequencing for evaluating the effect of KRAS status on anti-EGFR treatment response in colorectal cancer patients: a systematic review and meta-analysisPrognostic role of tumor PIK3CA mutation in colorectal cancer: a systematic review and meta-analysisDevelopment of a Whole Organism Platform for Phenotype-Based Analysis of IGF1R-PI3K-Akt-Tor Action.The frequencies and clinical implications of mutations in 33 kinase-related genes in locally advanced rectal cancer: a pilot study.EZH2 expression is a prognostic biomarker in patients with colorectal cancer treated with anti-EGFR therapeutics.Primary and acquired resistance to biologic therapies in gastrointestinal cancers.Detection of low-abundance KRAS mutations in colorectal cancer using microfluidic capillary electrophoresis-based restriction fragment length polymorphism method with optimized assay conditionsKRAS mutation testing in metastatic colorectal cancerCan we accurately report PTEN status in advanced colorectal cancer?Randomized phase Ib/II trial of rilotumumab or ganitumab with panitumumab versus panitumumab alone in patients with wild-type KRAS metastatic colorectal cancer.Telomere length is a novel predictive biomarker of sensitivity to anti-EGFR therapy in metastatic colorectal cancer.PTEN mRNA expression is less pronounced in left- than right-sided colon cancer: a retrospective observational studySomatic gene mutations in African Americans may predict worse outcomes in colorectal cancer.Novel drugs targeting the epidermal growth factor receptor and its downstream pathways in the treatment of colorectal cancer: a systematic reviewRoles of genetic variants in the PI3K/PTEN pathways in susceptibility to colorectal carcinoma and clinical outcomes treated with FOLFOX regimenTargeted therapies in colorectal cancer-an integrative view by PPPMPTEN expression is consistent in colorectal cancer primaries and metastases and associates with patient survival.Dietary restriction-resistant human tumors harboring the PIK3CA-activating mutation H1047R are sensitive to metforminEvidence-based appraisal of the upfront treatment for unresectable metastatic colorectal cancer patients.Genetic and epigenetic biomarkers for diagnosis, prognosis and treatment of colorectal cancerPIK3CA in Colorectal Cancer.Anti-epidermal growth factor receptor monoclonal antibody-based therapy for metastatic colorectal cancer: a meta-analysis of the effect of PIK3CA mutations in KRAS wild-type patients.Promising biomarkers for predicting the outcomes of patients with KRAS wild-type metastatic colorectal cancer treated with anti-epidermal growth factor receptor monoclonal antibodies: a systematic review with meta-analysis.MicroRNAs targeting EGFR signalling pathway in colorectal cancer.Anti-EGFR MoAb treatment in colorectal cancer: limitations, controversies, and contradictories.Beyond KRAS status and response to anti-EGFR therapy in metastatic colorectal cancer.Current and future biomarkers in the treatment of colorectal cancer.The Multidisciplinary Management of Colorectal Cancer: Present and Future Paradigms.Current Status and Perspectives Regarding LNA-Anti-miR Oligonucleotides and microRNA miR-21 Inhibitors as a Potential Therapeutic Option in Treatment of Colorectal Cancer.Association of MicroRNA-31-5p with Clinical Efficacy of Anti-EGFR Therapy in Patients with Metastatic Colorectal Cancer.Advances in Biomarkers: Going Beyond the Carcinoembryonic Antigen.
P2860
Q26766535-D4F6F160-A261-4781-B21B-818C59319BB2Q26768427-2C5BD9FF-11FA-4768-835C-ED3197AD7154Q26769850-8FA6872F-50A1-443D-9773-32E920B18BD7Q26795558-AB757915-E885-48E4-92C4-36729E4F0EE9Q27852105-F1A7C079-4AF8-4BC7-9A08-09095AA9DC4CQ27852988-57DB1E2B-DF8E-4FE7-975A-CE08B362DFBFQ28066460-747D170F-13EF-4998-AD94-0E1CC99821E8Q28077545-2D1751E7-B4EE-4011-BA66-EA2441D9BE69Q28082816-FB344A93-B32B-459C-A432-6BBA37CD9C50Q28543278-0ED96150-A65F-4199-8DC3-5DA10F152492Q30248900-0CD05A8B-6F5E-407B-9FFF-C90ABB0A3579Q30356087-DC4E161B-C8FB-4115-8CDA-E7DC26A895A6Q31157634-06586B88-5E02-403C-9ECB-41AC2D20ABACQ33566687-08CA9306-9732-4441-A519-8756CB5AC373Q33895573-165E5611-1407-483F-9C4D-570AB49F6531Q34565052-F61E4116-8790-479B-B26D-A8631FF2F73AQ34643960-40D2C906-24DD-45AD-8E92-7620A093B313Q35101357-1515CF70-8E06-49FC-8DAE-3CE8193CEDC2Q35212113-A2ADDCBD-4D6C-4E98-871F-50EE19832946Q35677265-D9377A7F-2C26-4E75-99C9-11D500C1875FQ36050773-DA09CBA5-60C6-465B-B714-4E4A5C41C980Q36108299-19947DCF-18ED-476C-B141-37844169BBFBQ36337063-F48DBB51-AB61-429C-BCAC-EED5015272D3Q36375442-DB6D0696-83A6-4A81-BCAE-249302F8A1D5Q36646911-6EEC93F0-8314-48C1-9F3C-5BBF146A4DB2Q37236257-6146A9D7-B940-49BE-8159-FBFD167E43D0Q37299288-D72D035B-9958-467B-A112-9333BD984B0EQ37408810-E5C49C02-0E79-4000-ABBC-E96E76FAFAADQ37578728-F8D3F98A-3863-42C1-9206-D8BD7DB7E444Q37612390-D7BB8545-8040-4645-BE71-77FDA1CA522AQ37636844-DD7037B9-5459-4F77-84B4-147B5F961054Q38089641-5D4B4816-1156-4579-B05D-C3347BA26BECQ38118612-BF9C1EF2-122E-4640-A597-CBC36E274945Q38219290-E5AA8C9B-0CB5-4B06-917A-F21A579E8150Q38222512-72FAF447-1F13-422A-821A-1B93FEC1E9A9Q38787244-E51D44F1-B793-4CB6-B6ED-98192C6DDA6DQ38825575-93D5153D-B8AC-413D-97EE-EC6CA149CCB1Q38841033-907EED0E-026D-432D-ACCD-EE38FF777332Q38932418-952197CC-F44B-4599-A5B3-D725C65992DEQ38943220-002B485F-0282-47FD-88D2-C00D4F355CC0
P2860
PTEN gene expression and mutations in the PIK3CA gene as predictors of clinical benefit to anti-epidermal growth factor receptor antibody therapy in patients with KRAS wild-type metastatic colorectal cancer.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
PTEN gene expression and mutat ...... metastatic colorectal cancer.
@ast
PTEN gene expression and mutat ...... metastatic colorectal cancer.
@en
type
label
PTEN gene expression and mutat ...... metastatic colorectal cancer.
@ast
PTEN gene expression and mutat ...... metastatic colorectal cancer.
@en
prefLabel
PTEN gene expression and mutat ...... metastatic colorectal cancer.
@ast
PTEN gene expression and mutat ...... metastatic colorectal cancer.
@en
P2093
P2860
P1476
PTEN gene expression and mutat ...... e metastatic colorectal cancer
@en
P2093
Andreas Kaubisch
Arjun Sood
Atrayee Basu-Mallick
Danielle McClain
Kathryn Tanaka
Lakshmi Rajdev
Radhashree Maitra
Raviraja Seetharam
Sanjay Goel
P2860
P304
P356
10.1016/J.CLCC.2011.12.001
P407
P577
2012-01-28T00:00:00Z